Post-transplant lymphoproliferative disorder (PTLD) is a polyclonal (benign) or clonal (malignant) proliferation of lymphoid cells that develops as a consequence of immunosuppression in a recipient of...
Comprehensive, easy-to-understand information about this condition
How we create this content →Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Feb 10, 2026
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 2 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning post-transplant lymphoproliferative disease
Updated Feb 16, 2026
A rare case report details gastrointestinal-localized polymorphic post-transplant lymphoproliferative disorder following kidney transplantation after allogeneic hematopoietic stem cell transplantation. This case highlights the complexities and potential complications in post-transplant care.
A Finnish nationwide study over 30 years analyzed survival and prognostic factors in 215 cases of post-transplant lymphoproliferative disorders. The findings contribute to understanding outcomes in patients following solid organ transplantation.
A case study highlights the occurrence of Epstein-Barr virus (EBV)-driven histiocytic sarcoma presenting as post-transplant lymphoproliferative disorder (PTLD) in a pediatric heart transplant patient. This finding underscores the need for awareness of EBV-related complications in transplant recipients.